Search results for

Peter Spours and Dan McCurdy explain why treating your patents like currency and researching competitors' portfolios can help you build a successful IP strategy

Jorge A Goldstein and Timothy J Shea, Jr look at how you can avoid inventorship disputes and explain how to resolve them when they occur

As companies strive for growth and new sources of value creation, many are turning to their IP portfolios as an asset base for exploitation. Managed intelligently as part of the corporate strategy, IP can become a key driving force behind revenue-generating transactions, provide lucrative licensing opportunities and be securitized against investment. However, if companies are to realize value from their IP, they must first ensure that their housekeeping is in order. Underestimating the importance of IP data management can be a risky business, particularly when it comes to licensing or merger and acquisition (M&A) activity.

As the Intellectual Property High Court (IPHC) enters its second year, Kazuo Ohtake of Nagashima Ohno & Tsunematsu assesses how far it has come

Canada's Supreme Court has clarified the protection available for famous trade marks, ruling that fame can extend to different goods and services.

Intellectual property protection is a "serious problem" in China, European Commissioner for External Trade Peter Mandelson said last month.

The patentability of methods for controlling the operation of medical devices has long been disputed in Japan. But, as Akihiko Okuno of Sonoda & Kobayashi in Tokyo explains, it is now possible to get protection – provided you draft your claims carefully

The Korean Supreme Court handed down a landmark ruling on April 27 2006, establishing a list of factors that must now be considered when calculating the reasonable royalty rate in all patent infringement cases.

The Mexican Law of Industrial Property (LIP) provides that use of a registered trade mark inures to the benefit of a registration only if it is effected directly by the registrant or by a recorded licensee.

Generic manufacturers operating in Ireland will welcome the recent introduction of legislation which enables them to conduct necessary pre-approval experiments without infringing the patent rights of the original manufacturer. The exemption is contained in new Irish regulations in the form of the European Communities (Limitation of Effect of Patent) Regulations, 2006 (the Irish Regulations) which implement certain sections of Directive 2004/27/EC (with respect to medicinal products for human use) and Directive 2004/28/EC (with respect to veterinary medicinal products).